George J. Hutton
Neurology
7200 Cambridge St
Houston, TX 77030
Houston, TX 77030
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 31, 2026
DIscontinuation of disease-modifying therapies in older adults with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: February 25, 2026
Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 03, 2025
Characteristics of myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitis.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: July 14, 2025
Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: March 04, 2025
Increased Intracranial Pressure in Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Journal: The neurologist
Published: December 02, 2024
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study.
Journal: Clinical pharmacology and therapeutics
Published: June 20, 2024
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States.
Journal: Preventive medicine
Published: June 20, 2024
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 02, 2024
Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Journal: Multiple sclerosis and related disorders
Published: January 18, 2024
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: December 14, 2023
Assessing treatment switch among patients with multiple sclerosis: A machine learning approach.
Journal: Exploratory research in clinical and social pharmacy
Published: April 26, 2023
Last Updated: 09/26/2026